ClinicalTrials.gg

Program

ziresovir

Also written as “AK0529”, “Ziresovir 125 mg” and “Ziresovir 500 mg”.

Its studies are mostly in Respiratory Syncytial Virus Infections, led by Shanghai Ark Biopharmaceutical.

Furthest: phase 3, since Jan 12, 202012 company-led studies, 1 open or runningNext primary completion: Dec 2028 (phase 3)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Shanghai Ark Biopharmaceutical121 open or runningphase 3since Jan 12, 2020Nov 11, 2014Dec 2028phase 3 · NCT07658534

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Nov 11, 2014First study: phase 1 study in Respiratory Syncytial Virus InfectionsFirst studyNCT02297594 · 74 enrolled · Australia
  2. May 27, 2015Phase 1 study in Respiratory Syncytial Virus InfectionsNCT02460016 · 1 enrolled · Australia
  3. Jan 4, 2016Phase 2 study in Respiratory Syncytial Virus InfectionsNCT02654171 · 72 enrolled · Australia, Hong Kong, Israel and more
  4. Oct 19, 2017Phase 1 study in HealthyNCT03322800 · 51 enrolled · China
  5. Jan 10, 2018Phase 1 study in HealthyNCT03400995 · 7 enrolled · United Kingdom
  6. Oct 5, 2018Phase 2 study in Respiratory Syncytial Virus InfectionsNCT03699202 · 1 enrolled · China
  7. Jan 12, 2020Phase 3 study in Respiratory Syncytial Virus InfectionsNCT04231968 · 311 enrolled · China
  8. Feb 1, 2021Phase 1 study in Healthy SubjectsNCT04788017 · 24 enrolled · United States
  9. Mar 24, 2023Phase 2 study in Respiratory Syncytial Virus InfectionsNCT06942299 · 25 enrolled · China
  10. Sep 4, 2024Phase 1 study in Healthy VolunteersNCT06591845 · 34 enrolled · United States
  11. Dec 16, 2024Phase 3 study in Respiratory Synctial Virus InfectionsNCT06775405 · 180 enrolled · China
  12. Mar 30, 2026Phase 3 study in Respiratory Syncytial Virus InfectionsNCT07658534 · 290 planned · China

Ahead

  1. Dec 2028Primary completion: phase 3 study in Respiratory Syncytial Virus InfectionsNCT07658534

TargetBeta

A vaccine: it acts on a pathogen, not a human gene.

“Fusion glycoprotein F0 inhibitor”ChEMBL 37, by rule

Studies

All 12 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT07658534Respiratory Syncytial Virus Infections · China3RecruitingDec 2028290
NCT06775405Respiratory Synctial Virus Infections · China3CompletedApr 7, 2025180
NCT06591845Healthy Volunteers · United States1CompletedDec 16, 202434
NCT06942299Respiratory Syncytial Virus Infections · China2CompletedJun 28, 202425
NCT04788017Healthy Subjects · United States1CompletedJun 14, 202124
NCT04231968Respiratory Syncytial Virus Infections · China3CompletedJan 21, 2022311
NCT03699202Respiratory Syncytial Virus Infections · China2TerminatedApr 4, 20191
NCT03400995Healthy · United Kingdom1CompletedFeb 27, 20187
NCT03322800Healthy · China1CompletedApr 6, 201851
NCT02654171Respiratory Syncytial Virus Infections · Australia, Hong Kong, Israel and more2CompletedMar 31, 201972
NCT02460016Respiratory Syncytial Virus Infections · Australia1TerminatedNov 3, 20151
NCT02297594Respiratory Syncytial Virus Infections · Australia1CompletedJun 201574

How it is read

Names in the registry

  • “AK0529”, 10 entries
  • “Ziresovir 125 mg”, 1 entry
  • “Ziresovir 500 mg”, 1 entry
  • “Ziresovir (AK0529)”, 1 entry
  • “Ziresovir”, 1 entry

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.
ziresovir (Shanghai Ark Biopharmaceutical): development program | ClinicalTrials.gg